SG11202005200XA - Prostate cancer specific marrow infiltrating lymphocytes and uses thereof - Google Patents
Prostate cancer specific marrow infiltrating lymphocytes and uses thereofInfo
- Publication number
- SG11202005200XA SG11202005200XA SG11202005200XA SG11202005200XA SG11202005200XA SG 11202005200X A SG11202005200X A SG 11202005200XA SG 11202005200X A SG11202005200X A SG 11202005200XA SG 11202005200X A SG11202005200X A SG 11202005200XA SG 11202005200X A SG11202005200X A SG 11202005200XA
- Authority
- SG
- Singapore
- Prior art keywords
- prostate cancer
- infiltrating lymphocytes
- cancer specific
- marrow infiltrating
- specific marrow
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862646649P | 2018-03-22 | 2018-03-22 | |
PCT/US2019/023543 WO2019183455A1 (en) | 2018-03-22 | 2019-03-22 | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005200XA true SG11202005200XA (en) | 2020-07-29 |
Family
ID=67986362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005200XA SG11202005200XA (en) | 2018-03-22 | 2019-03-22 | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210000876A1 (en) |
EP (1) | EP3735256A4 (en) |
JP (1) | JP2021516666A (en) |
KR (1) | KR20200135936A (en) |
CN (1) | CN112074280A (en) |
AU (1) | AU2019240420A1 (en) |
CA (1) | CA3084179A1 (en) |
IL (1) | IL277482A (en) |
MX (1) | MX2020006131A (en) |
SG (1) | SG11202005200XA (en) |
WO (1) | WO2019183455A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017002852A (en) * | 2014-09-04 | 2017-05-30 | Univ Johns Hopkins | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions. |
EP3841117A4 (en) * | 2018-11-05 | 2023-01-18 | Windmil Therapeutics, Inc. | Marrow infiltrating lymphocytes with increased clonality and uses thereof |
KR20210098485A (en) * | 2018-11-30 | 2021-08-10 | 윈드밀 테라퓨틱스, 인크. | Bone marrow infiltrating lymphocytes (MILs) expressing a chimeric antigen receptor (CAR), methods of making them and methods of using them in therapy |
WO2020198031A1 (en) * | 2019-03-22 | 2020-10-01 | Windmil Therapeutics Inc. | Lung cancer specific marrow infiltrating lymphocytes and uses thereof |
US20230100744A1 (en) * | 2020-02-28 | 2023-03-30 | Windmil Therapeutics, Inc. | Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
IL151287A0 (en) | 2000-02-24 | 2003-04-10 | Xcyte Therapies Inc | A method for stimulation and concentrating cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
MX2017002852A (en) | 2014-09-04 | 2017-05-30 | Univ Johns Hopkins | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions. |
AU2016268864B2 (en) | 2015-05-28 | 2022-06-02 | Kite Pharma, Inc. | Methods of conditioning patients for T cell therapy |
MA42902A (en) | 2015-07-08 | 2018-05-16 | Univ Johns Hopkins | MARINAL-INFILTRATING LYMPHOCYTES (MIL) AS A SOURCE OF T-LYMPHOCYTES FOR CHEMERIC ANTIGEN RECEPTOR (CAR) THERAPY |
GB201608918D0 (en) * | 2016-05-20 | 2016-07-06 | Aslan Pharmaceuticals Pte Ltd | Method |
-
2019
- 2019-03-22 KR KR1020207019974A patent/KR20200135936A/en active Search and Examination
- 2019-03-22 AU AU2019240420A patent/AU2019240420A1/en not_active Abandoned
- 2019-03-22 WO PCT/US2019/023543 patent/WO2019183455A1/en unknown
- 2019-03-22 MX MX2020006131A patent/MX2020006131A/en unknown
- 2019-03-22 CN CN201980021186.XA patent/CN112074280A/en active Pending
- 2019-03-22 EP EP19770414.1A patent/EP3735256A4/en active Pending
- 2019-03-22 US US16/982,906 patent/US20210000876A1/en not_active Abandoned
- 2019-03-22 CA CA3084179A patent/CA3084179A1/en active Pending
- 2019-03-22 JP JP2020541595A patent/JP2021516666A/en active Pending
- 2019-03-22 SG SG11202005200XA patent/SG11202005200XA/en unknown
-
2020
- 2020-09-21 IL IL277482A patent/IL277482A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021516666A (en) | 2021-07-08 |
CA3084179A1 (en) | 2019-09-26 |
AU2019240420A1 (en) | 2020-06-25 |
IL277482A (en) | 2020-11-30 |
US20210000876A1 (en) | 2021-01-07 |
WO2019183455A1 (en) | 2019-09-26 |
MX2020006131A (en) | 2020-08-17 |
EP3735256A4 (en) | 2021-10-13 |
EP3735256A1 (en) | 2020-11-11 |
KR20200135936A (en) | 2020-12-04 |
CN112074280A (en) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277482A (en) | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof | |
ZA202002923B (en) | Cd47 antibodies and uses thereof for treating cancer | |
IL266655A (en) | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same | |
HRP20210709T8 (en) | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | |
SG11202010890PA (en) | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto | |
EP3576781A4 (en) | Neoantigens and uses thereof for treating cancer | |
EP3134115A4 (en) | Methods and compositions for treating metastatic breast cancer and other cancers in the brain | |
EP3481941A4 (en) | Breast and ovarian cancer methylation markers and uses thereof | |
IL284561A (en) | Prostate neoantigens and their uses | |
IL271328A (en) | Compositions and methods for enhancing cancer chemotherapy | |
GB201806064D0 (en) | Improved Classification And Prognosis Of Prostate Cancer | |
EP3589732A4 (en) | Detecting prostate cancer | |
IL282936A (en) | Marrow infiltrating lymphocytes with increased clonality and uses thereof | |
IL272487B (en) | Antibodies useful in cancer diagnosis | |
SG11202002733UA (en) | Cancer risk evaluation method and cancer risk evaluation system | |
SG11202109835WA (en) | Methods for predicting prostate cancer and uses thereof | |
EP3363461A4 (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
IL282308A (en) | Novel cancer antigens and methods | |
EP3405583A4 (en) | Compositions and methods for screening and identifying clinically aggressive prostate cancer | |
EP3675893A4 (en) | Methods for treating and diagnosing metastatic liver cancer | |
SG11202002529TA (en) | Ovarian cancer biomarker and use thereof | |
EP3593138A4 (en) | Compositions and methods for treating cancer with anti-renalase antibodies and anti-pd1 antibodies | |
EP3290054A4 (en) | Tumor cell malignant transformation suppressor and anti-tumor agent | |
EP3388448A4 (en) | Marker for pancreatic cancer and intraductal papillary mucinous tumors | |
PL3643707T3 (en) | 18f-labelled compound for prostate cancer diagnosis, and use thereof |